Related Experiment Video

Updated: Feb 5, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K

Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation

Kunihiko Miyazaki1, Tomohiro Tamura2, Takayuki Kaburagi2

  • 1Division of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan.

Anticancer Research
|September 9, 2018
PubMed
Abstract

Insights

Afatinib therapy shows similar outcomes in non-small cell lung cancer patients with acquired EGFR T790M mutations, regardless of prior tyrosine kinase inhibitor (TKI) treatment. Appropriate strategies can overcome challenges in clinical practice.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) treatment landscape.
  • Acquired resistance mutations like EGFR T790M pose challenges.
  • Afatinib as a targeted therapy option.

Purpose of the Study:

  • Evaluate real-world clinical outcomes of afatinib in NSCLC patients with acquired EGFR T790M mutations.
  • Assess the impact of prior tyrosine kinase inhibitor (TKI) therapy on afatinib efficacy.
  • Determine if pretreatment and T790M mutation status affect overall survival.

Main Methods:

  • Retrospective chart review from January 2013 to November 2017.
  • Inclusion of 74 NSCLC patients with acquired EGFR T790M mutations.
  • Analysis of treatment outcomes stratified by TKI pretreatment and T790M mutation presence.

Main Results:

  • Afatinib treatment outcomes were consistent with previous clinical trials.
  • No statistical difference in overall survival was observed based on TKI pretreatment or T790M mutation status.
  • Patient stratification revealed similar survival rates across different treatment subgroups.

Conclusions:

  • Real-world data support afatinib's efficacy in NSCLC patients with acquired EGFR T790M mutations.
  • Pretreatment and absence of T790M mutation disadvantages can be managed with effective treatment strategies.
  • Population-based study highlights the importance of tailored treatment approaches in clinical practice.
Keywords:
Clinical practiceacquired T790M mutationafatinibimmune-checkpoint inhibitornon-small cell lung cancerosimertinib

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.3K

Related Concept Videos

Mutations01:39

Mutations

Overview
94.5K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.6K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Mutation, Gene Flow, and Genetic Drift01:09

Mutation, Gene Flow, and Genetic Drift

In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
64.4K
Mutations in Microorganisms01:18

Mutations in Microorganisms

Mutations are heritable changes in an organism’s genome involving alterations in the base sequence of DNA or RNA. These changes can influence cellular processes and phenotypic traits, potentially transforming the unaltered wild type into a mutant form. Such changes, termed forward mutations, are pivotal in shaping the genetic diversity of organisms.RNA viruses exhibit the highest mutation rates due to the absence of robust proofreading mechanisms during genome replication. In contrast,...
741